Nanostics Announces Publication of a ClarityDX Prostate Study Validating New Algorithms with Improved Cancer Prediction that make MRI or DRE Optional

EDMONTON, AB, April 20, 2026 /PRNewswire/ - Nanostics Inc., a precision health company advancing diagnostic innovation through its ClarityDX® platform, today announced the publication of a peer-reviewed study in npj Digital Medicine validating its AI-driven ClarityDX® Prostate models for...